Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

Excerpt from the Press Release:

HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restricted, soft pan-JAK inhibitor, for the treatment of atopic dermatitis (AD).

This randomized, double-blind, vehicle-controlled Phase II study evaluated the efficacy and safety of topical LNK01004 ointment (0.3% and 1.0%) in adult patients with moderate-to-severe AD. A total of 75 patients were enrolled and randomized in a 1:1:1 ratio to receive LNK01004 0.3%, LNK01004 1.0%, or vehicle ointment twice daily (BID) for 8 weeks. Eligible patients had a vIGA-AD score of 3 or 4 and BSA involvement between 5% and 35%.

Efficacy results demonstrated that after 8 weeks of treatment, both LNK01004 dose groups achieved higher EASI-75 response rates than the vehicle group, with more pronounced benefits in patients with higher baseline BSA. Among patients with BSA ≥10%, the EASI-75 response rates for the 0.3%, 1.0%, and vehicle groups were 61.1%, 46.2%, and 20% respectively. The vIGA-AD (score 0/1 with ≥2-point improvement) response rates were 44.4%, 38.5%, and 10%, respectively. In patients with BSA ≥20%, both LNK01004 groups showed even greater clinical improvements, further supporting its potential as a treatment for moderate-to-severe AD.

Click the button below to read the entire Press Release:

Continue Reading The Press Release